Narrow search
Showing 1 - 10 of 467
Cover Image
Globalization and the Price Decline of Illicit Drugs
Costa Storti, Claudia; De Grauwe, Paul - 2021
decline has tended to offset the effects of drug policies aimed at reducing drug use in major industrial countries. The main … margin (the difference between the retail and producer prices) in the drug business. We develop the hypothesis, and give some … some thoughts about the effects of globalization on the effectiveness of drug policies and argue that globalization may …
Persistent link: https://www.econbiz.de/10013317059
Cover Image
'High' Achievers? Cannabis Access and Academic Performance
Marie, Olivier; Zölitz, Ulf - 2021
This paper investigates how legal cannabis access affects student performance. Identification comes from an exceptional policy introduced in the city of Maastricht which discriminated legal access based on individuals’ nationality. We apply a difference-in-difference approach using...
Persistent link: https://www.econbiz.de/10013315545
Cover Image
The War on Illegal Drugs in Producer and Consumer Countries : A Simple Analytical Framework
Mejia, Daniel - 2021
the trade-off faced by the government of the drug consumer country between prevention policies (aimed at reducing the …
Persistent link: https://www.econbiz.de/10013316449
Cover Image
Choosing Among Competing Blockbusters : Does the Identity of the Third-Party Payer Matter for Prescribing Doctors?
Dalen, Dag Morten - 2010
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8% of total pharmaceutical sale in Norway. With use of a unique natural policy experiment in Norway, this paper examines to what extent the identity of the...
Persistent link: https://www.econbiz.de/10013136585
Cover Image
A Probability Approach to Pharmaceutical Demand and Price Setting : Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?
Dalen, Dag Morten - 2011
TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what...
Persistent link: https://www.econbiz.de/10013118139
Cover Image
Health Insurance and Diversity of Treatment : A Policy Mix Perspective
Bardey, David - 2013
We determine the optimal health policy mix when the average utility of patients increases with the supply of drugs available in a therapeutic class. Health risk coverage rely on two instruments, copayment and reference pricing, that affect the supported risk composed by health expenses and...
Persistent link: https://www.econbiz.de/10013086413
Cover Image
Margins and Market Shares : Pharmacy Incentives for Generic Substitution
Brekke, Kurt Richard - 2013
generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …
Persistent link: https://www.econbiz.de/10013088216
Cover Image
Explaining Early Adoption on New Medicines : Regulation, Innovation and Scale
Varol, Nebibe - 2014
Understanding how price regulations affect the adoption of new patent-protected pharmaceutical technologies is a crucial question in designing health systems. This paper addresses this question by examining how price expectations shape the probability of launch, controlling for competition,...
Persistent link: https://www.econbiz.de/10013067984
Cover Image
Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008
Varol, Nebibe - 2014
Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...
Persistent link: https://www.econbiz.de/10013068052
Cover Image
The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France
Lichtenberg, Frank R. - 2014
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10013069689